表紙：急性呼吸窮迫症候群治療の市場規模、シェア、成長分析、薬剤クラス別、投与経路別、流通チャネル別、地域別 - 産業予測、2025年～2032年

市場調査レポート

商品コード

1764766

急性呼吸窮迫症候群治療の市場規模、シェア、成長分析、薬剤クラス別、投与経路別、流通チャネル別、地域別 - 産業予測、2025年～2032年

Acute Respiratory Distress Syndrome Treatment Market Size, Share, and Growth Analysis, By Drug Class, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年07月03日
発行: SkyQuest
ページ情報: 英文 192 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 782,598円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 915,492円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,048,386円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.66円

全表示
概要
目次

概要

サンプル依頼リストに入れる

急性呼吸窮迫症候群治療の世界市場規模は、2023年に39億米ドルと評価され、予測期間（2025～2032年）にCAGR 5.8％で成長し、2024年の41億3,000万米ドルから2032年には64億8,000万米ドルに成長する見通しです。

急性呼吸窮迫症候群（ARDS）治療市場は、呼吸器疾患の有病率の増加、高齢化、汚染レベルの上昇、生活習慣の進化などの要因に後押しされ、大きく成長する見通しです。COVID-19パンデミック後の意識の高まりと政府の後押しが、非侵襲的換気法と体外膜酸素療法（ECMO）の進歩に拍車をかけ、治療成果を向上させ、薬剤、人工呼吸器、ICUリソースに対する市場の需要を促進しています。さらに、高齢者層は特に重度の肺疾患に罹患しやすく、患者層が拡大しています。しかし、市場は、高い治療費、熟練した専門家の不足、診断の遅れ、革新的な治療法の導入を妨げる規制上のハードルなどの課題に直面しており、利害関係者に機会と障害の両方をもたらしています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

Biomarck Pharmaceuticals
Athersys
Healios
Direct Biologics
Arch Biopartners
APEPTICO Forschung und Entwicklung GmbH
Staidson（Beijing）Biopharmaceuticals
MediciNova
Edesa Biotech
Light Chain Biosciences
Boehringer Ingelheim
Genentech
Windtree Therapeutics
Veru
Mesoblast Limited
Avalo Therapeutics
Pluristem Therapeutics
ILTOO Pharma

結論と提言

Product Code: SQMIG35I2402

Global Acute Respiratory Distress Syndrome Treatment Market size was valued at USD 3.9 billion in 2023 and is poised to grow from USD 4.13 billion in 2024 to USD 6.48 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The Acute Respiratory Distress Syndrome (ARDS) Treatment Market is poised for significant growth, fueled by factors such as the increasing prevalence of respiratory disorders, an aging population, escalating pollution levels, and evolving lifestyle habits. Heightened awareness and government backing following the COVID-19 pandemic have spurred advancements in non-invasive ventilation methods and extracorporeal membrane oxygenation (ECMO), enhancing treatment outcomes and propelling market demand for drugs, ventilators, and ICU resources. Furthermore, the geriatric demographic is particularly susceptible to severe lung conditions, broadening the patient base. However, the market faces challenges, including high treatment costs, a shortage of skilled professionals, delayed diagnoses, and regulatory hurdles that can impede the introduction of innovative therapies, presenting both opportunities and obstacles for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Respiratory Distress Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Respiratory Distress Syndrome Treatment Market Segments Analysis

Global Acute Respiratory Distress Syndrome Treatment Market is segmented by Drug Class, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Vasoconstrictors, Bronchodilators, Steroids and Antibiotics, Nitric Oxide, Sedatives & Paralytics, Surfactant and Others. Based on Route of Administration, the market is segmented into Oral, Injection and Inhalation. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Respiratory Distress Syndrome Treatment Market

The rising prevalence of respiratory ailments such as pneumonia, chronic obstructive pulmonary disease (COPD), and post-COVID syndrome significantly drives the Global Acute Respiratory Distress Syndrome (ARDS) Treatment market. Contributing factors, including air pollution and smoking, are exacerbating the global patient demographic. This trend highlights an escalating need for expedited diagnostics and enhanced intensive care unit (ICU) capabilities in both developed and developing regions. The increasing burden of these respiratory conditions underscores the urgency for innovative treatment options and improved healthcare infrastructure, ultimately fueling market growth and shaping the future of ARDS management across the globe.

Restraints in the Global Acute Respiratory Distress Syndrome Treatment Market

The lack of FDA-approved medications specifically designed for Acute Respiratory Distress Syndrome (ARDS) limits the available treatment options and stifles pharmaceutical innovation. Current therapies are often adaptations from treatments intended for other inflammatory or respiratory diseases, leading to variable results. This regulatory gap disrupts the establishment of standardized treatment protocols, which in turn hampers investment in the development of targeted therapies. Consequently, the overall growth of the ARDS treatment market, both clinically and commercially, is significantly hindered as stakeholders remain cautious about pursuing advancements in this area due to the associated challenges and uncertainties.

Market Trends of the Global Acute Respiratory Distress Syndrome Treatment Market

The Global Acute Respiratory Distress Syndrome (ARDS) Treatment market is witnessing a transformative trend driven by the integration of AI technologies in personalized medicine. These advanced solutions are enabling healthcare providers to develop tailored treatment plans that leverage patient-specific information, including genetic profiles, biomarkers, and real-time clinical data. This shift towards AI-driven personalized ARDS treatment is anticipated to enhance therapeutic efficacy significantly, resulting in improved patient outcomes and reduced mortality rates. As critical care management evolves with AI optimization, this trend is poised to reshape therapeutic strategies, positioning itself as a pivotal force in the future landscape of ARDS treatment.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Case Studies

Global Acute Respiratory Distress Syndrome Treatment Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Vasoconstrictors
Bronchodilators
Steroids and Antibiotics
Nitric Oxide
Sedatives & Paralytics
Surfactant
Others

Global Acute Respiratory Distress Syndrome Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Injection
Inhalation

Global Acute Respiratory Distress Syndrome Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Global Acute Respiratory Distress Syndrome Treatment Market Size & CAGR (2025-2032)

North America (Drug Class, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Drug Class, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Biomarck Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athersys
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Healios
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Direct Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arch Biopartners
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
APEPTICO Forschung und Entwicklung GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Staidson (Beijing) Biopharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediciNova
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Edesa Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Light Chain Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Windtree Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Veru
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avalo Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pluristem Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ILTOO Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

急性呼吸窮迫症候群治療の市場規模、シェア、成長分析、薬剤クラス別、投与経路別、流通チャネル別、地域別 - 産業予測、2025年～2032年

Acute Respiratory Distress Syndrome Treatment Market Size, Share, and Growth Analysis, By Drug Class, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

急性呼吸窮迫症候群治療市場規模：薬剤クラス別& CAGR（2025-2032）

急性呼吸窮迫症候群治療市場規模：投与経路別& CAGR（2025-2032）

急性呼吸窮迫症候群治療市場規模：流通チャネル別& CAGR（2025-2032）

急性呼吸窮迫症候群治療市場規模：地域別& CAGR（2025-2032）